John Martin talks about the successful Progenza STEP trial and the granting of a Japanese patent for the company's platform technology.
Milestone payments made for the technology has moved the balance sheet into postitive revenue as the company prepares for licensing in Japan, with expectation of flow through licensing in other countries to follow.
Regeneus Ltd will be presenting to the BioJapan 2017 Conference in Yokohama from October 11 to October 13. To visit the conference website, please visit:
To view the video interview, please visit:
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Regeneus Ltd (ASX:RGS) Enters Into Collaborative Agreement With Asahi Glass (TYO:5201) To Commercialize Progenza
Regeneus Ltd (ASX:RGS) Progenza Granted Advanced Therapy Medicinal Product Designation by European Medicines Agency
Regeneus Ltd (ASX:RGS) Appoints Japan-Based Non-Executive Director with Extensive Pharmaceutical Industry Experience